

I. Biparametric packages

Fluofarma multiplexed High Content Screening assays simultaneously measuring complementary parameters will permit faster characterization of your candidate entity and enhance your categorization capability.

- Caspase 3/7 activity & Cytolysis:

Discriminates whether a candidate entity induces cell death through apoptosis or has a pure cytolytic effect.

- Caspase 3/7 activity & Proliferation:

Discriminates whether a candidate entity selectively inhibits proliferation or induces growth arrest and apoptosis.

- Caspase 3/7 activity & Cell Cycle:

Discriminates the synergy or antagonism of the effects on cell division and apoptosis of a candidate entity by measuring the percentage of apoptotic cells in each phase of the cell cycle.

- Caspase 3/7 activity & Mitochondrial Electrical Potential:

Discriminates candidate entities that induce apoptosis by primary activation of mitochondrial permeability from those that primarily activate caspase 3/7.

II. Discovery packages

These packages will enable you to discover whether your entity can help fight cancer, and how.

They include evaluation of the following parameters:

- Caspase 3/7 activity
- Cytolysis
- Cell division
- Angiogenesis
- Cell senescence
- Mitochondrial potential
- Cell cycle

Analyzing the effects of an entity on these different parameters will enable you:

- To understand the principal anticancer effect of your entity: induction of cell death, arrest of cell division, inhibition of angiogenesis or combinations of any of these.

- For entities that primarily induce cell death, to understand whether their mechanism of action involves cytolysis, caspase activation and/or mitochondrial depolarization.
- For entities that have a pure cytostatic effect, to evaluate their efficacy to further induce cell death by provoking cell senescence.
- For entities that exhibit both cytostatic and apoptotic properties, to reveal the synergy or antagonism of the two effects.

III. Therapeutic efficacy packages

These packages will enable you to gain insight as to the potential therapeutic efficacy of your entity in future *in vivo* models.

They include evaluation of the following parameters after a short treatment time (4 to 72 hours) or following chronic treatment (7 to 14 days):

- Inhibition of cell migration
- Inhibition of cell invasion
- Inhibition of clonal growth
- Inhibition of endothelial tube formation

These tests will take evaluation of your compound a step further by providing crucial information concerning the metastasis production mechanism: angiogenesis, migration and invasion of neighboring tissue followed by clonal expansion of tumor cells.

IV. Flexibility

These HCS assays can be performed across a Fluofarma panel of tumor cell lines and/or in Fluofarma recombinant cell lines expressing a proprietary biosensor for measuring Caspase 3/7 activity in living cells. Fluofarma can flexibly maintain and use the client's own cell lines.

For detailed information relating to Fluofarma HCS assays, timelines and costs, please contact us.

Contact:

Fluofarma, 2 Rue Robert Escarpit - 33600 Pessac – France
Tel: +33 (0) 5 4000 3060 - Fax : +33 (0)5 4000 3008 – Email : business@fluofarma.com
www.fluofarma.com